Indapamid
When ATH:
C03BA11
Characteristic.
White or off-white crystalline powder, soluble in aqueous solutions of strong alkalies.
Pharmacological action.
Diuretic, vazodilatirtee, gipotenzivnoe.
Application.
Arterial hypertension, congestive heart failure.
Contraindications.
Hypersensitivity, cerebrovascular accidents, severe liver failure, diabetes decompensated, gout, Pregnancy and breast-feeding (at the time of treatment should abandon breastfeeding).
Side effects.
Weakness, orthostatic hypotension, kaliopenia, hyperuricemia, nausea, epigastric pain, diarrhea, convulsions, allergic reactions.
Cooperation.
It enhances the effect of antihypertensive drugs, increases the risk of hypokalemia in the background kaliyvyvodyaschih diuretics.
Overdose.
Symptoms: weakness, disruption of water and electrolyte balance, respiratory depression, hypotension.
Treatment: Correction fluid and electrolyte balance, possible gastric lavage.
Dosing and Administration.
Inside, by 2,5 mg or 1,5 mg (tabl.retard) per day (preferably in the morning). The maximum daily dose - 10 mg.
Precautions.
In appointing the patients with diseases of the liver and kidneys need to monitor the level of potassium in the blood. In patients with hyperuricemia to regularly determine the content of uric acid in the blood. Not to be combined with lithium, vynkamynom, kaliyvyvodyaschimi diuretics.
Cooperation
| Active substance | Description of interaction |
| Amlodipine | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Atenolol | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Betaksolol | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Betametazon | FMR: synergism. Intensifies (mutually) electrolyte spillage, especially potassium, It increases the risk of hypokalemia. |
| Bisoprolol | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Buprenorphine | FMR. It increases the likelihood of orthostatic hypotension. |
| Valsartan | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Warfarin | FMR: synergism. Against the background of enhanced effect of indapamide. |
| Verapamil | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Gidrokortizon | FMR: synergism. Intensifies (mutually) electrolyte spillage, especially potassium, It increases the risk of hypokalemia. |
| Gidroxlorotiazid | FMR: synergism. Strengthens (mutually) effects. |
| Glipizide | FMR: antagonizm. Against the background of weakened effect of indapamide; with a joint appointment requires constant monitoring of blood glucose concentrations. |
| Dexamethasone | FMR: synergism. Intensifies (mutually) electrolyte spillage, especially potassium, It increases the risk of hypokalemia. |
| Digoxin | FMR. Against the background of indapamide, enhancing potassium loss, amplified and accelerated manifestation of cardiotoxicity. |
| Diltiazem | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Doksazozin | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Insulin aspart | FMR: antagonizm. Against the background of weakened effect of indapamide; the combined appointment may need to increase the dose. |
| Insulin dvuhfaznыy [human genetic engineering] | FMR: antagonizm. Against the background of weakened effect of indapamide; the combined appointment may need to increase the dose. |
| Insulin soluble [pork monocomponent] | FMR: antagonizm. Against the background of weakened effect of indapamide; the combined appointment may need to increase the dose. |
| Irbesartan | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Candesartan cïleksetïl | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Captopril | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Klonidin | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Codeine | FMR: synergism. It increases the likelihood of orthostatic hypotension. |
| Kortizon | FMR: synergism. Intensifies (mutually) electrolyte spillage, especially potassium, It increases the risk of hypokalemia. |
| Lisinopril | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Lithium carbonate | FKV. FMR. Against the background of indapamide, inducing natriuresis, reduced isolation and increased risk of toxic effects. |
| Lozartan | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Methyldopa | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Methylprednisolone | FMR: synergism. Intensifies (mutually) electrolyte spillage, especially potassium, It increases the risk of hypokalemia. |
| Metoprolol | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Minoksidil | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Morphine sulfate | FMR: synergism. It increases the likelihood of orthostatic hypotension. |
| Moexipril | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Nadolol | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Nitroglycerin | FMR: synergism. Against the backdrop of intensified antihypertensive effect of indapamide. |
| Nifedipine | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Norepinephrine | FMR: antagonizm. Against the background of the effect of indapamide reduced. |
| Perindopril | FKV. FMR. Strengthens (mutually) hypotensive effect. Against the background of reduced bioavailability of indapamide. |
| Pindolol | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Prazosin | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Prednisolone | FMR: synergism. Intensifies (mutually) electrolyte spillage, especially potassium, It increases the risk of hypokalemia. |
| Propranolol | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Ramipril | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Risperidone | FMR: synergism. Against the background of indapamide causes clinically significant hypotension. |
| Sotalol | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Spirapril | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Telmisartan | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Terazosin | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Timolol | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Trandolapril | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Triamcinolone | FMR: synergism. Intensifies (mutually) electrolyte spillage, especially potassium, It increases the risk of hypokalemia. |
| Felodipine | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Phenobarbital | FMR: synergism. It increases the risk of orthostatic hypotension. |
| Fentanyl | FMR: synergism. It increases the likelihood of orthostatic hypotension. |
| Fludrokortizon | FMR: synergism. Intensifies (mutually) electrolyte spillage, especially potassium, It increases the risk of hypokalemia. |
| Fosinopril | FMR. Strengthens (mutually) hypotensive effect, reduces the loss of potassium. |
| Furosemid | FMR: synergism. Strengthens (mutually) effects. |
| Xlortalidon | FMR: synergism. Strengthens (mutually) effects. |
| Enalapril | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Enalaprilat | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Eprosartan | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Esmolol | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Ethanol | FMR: synergism. It increases the risk of orthostatic hypotension. |
